Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Oral Communications

Pituitary Clinical

ea0041oc13.1 | Pituitary Clinical | ECE2016

Acromegaly is associated with increased cancer risk: a nationwide survey in Italy on behalf of the Italian study group of acromegaly

Reimondo Giuseppe , Terzolo Massimo , Berchialla Paola , Malchiodi Elena , Arosio Maura

Introduction: That acromegaly may cause cancer remains an unsolved issue. Aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in a nationwide multicenter cohort study in Italy on acromegalic patients who have been treated in the somatostatin-receptor ligands era.Methods and design: We have evaluated the prevalence of neoplasia from a series of 1512 patients who were proactively followed in 24 terti...

ea0041oc13.2 | Pituitary Clinical | ECE2016

Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

Dal Jakob , Lundby Hoyer Katrine , Pedersen Steen B , Magnusson Nils , Bjerrring Peter , Frystyk Jan , Moller Niels , Jessen Niels , Jorgensen Jens Otto L

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...

ea0041oc13.3 | Pituitary Clinical | ECE2016

Increased glucocorticoid replacement doses are associated with excess mortality in patients with non-functioning pituitary adenoma

Hammarstrand Casper , Hallen Tobias , Andersson Eva , Skoglund Thomas , Nilsson Anna G , Ragnarsson Oskar , Johannsson Gudmundur , Olsson Daniel S

Background: Patients with secondary adrenal insufficiency have an excess mortality. Data concerning the influence of the glucocorticoid replacement regime on mortality is sparse.Objective: To investigate if the total daily dose of glucocorticoid replacement has an effect on mortality in patients with non-functioning pituitary adenoma (NFPA).Method: Patients with NFPA treated for hypopituitarism in the western region of Sweden were ...

ea0041oc13.4 | Pituitary Clinical | ECE2016

Diagnosis and management of thyrotropin-secreting pituitary tumors: a single center experience with a long-term follow-up of 30 patients

Capraru Oana-Maria , Gaillard Celine , Vasiljevic Alexandre , Raverot Veronique , Borson-Chazot Francoise , Jouanneau Emmanuel , Raverot Gerald

TSH secreting pituitary adenomas are rare tumours for which the treatment of choice is neurosurgery but in some cases medical treatment with somatostatin analogs (SSA) can lead to a good control of symptoms and shrinkage of the tumour.The objective of this study was to review 30 patients diagnosed with TSH-omas between October 1981–July 2014, followed-up for a median of 43.93 months (1.12–192.11) in our University Hospital from Lyon, France.</p...

ea0041oc13.5 | Pituitary Clinical | ECE2016

Unmet health and information needs of women with hypogonadotropic hypogonadism

Dwyer Andrew , Quinton Richard , Morin Diane , Pitteloud Nelly

Background: Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder (1:4′000-10′000) characterized by absent puberty and infertility. There is striking gender discordance (3–4 males for each female case) thus women with CHH are the “rarest of the rare”. Unlike many orphan conditions, treatments are available and hormonal therapies are effective for inducing puberty and fertility. However, the presumable availability of treatment does not ne...